Skip to main content

Table 2 The baseline characteristics in the nafamostat mesilate and the control groups after matching

From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis

  Nafmostat mesilate (n = 201) Control (n = 106) Total (N = 307) P value
Age, y, median (range) 68 (55–75) 65 (52–73) 66 (54–75) 0.202
Male (%) 74 (36.8) 47 (44.3) 121 (39.4) 0.186
History of AP (%) 3 (1.5) 0 3 (1.0)  
SOD (%) 2 (1.0) 0 2 (0.7)  
Purpose of ERCP (%)
 Choledocholithiasis 120 (59.7) 56 (52.8) 176 (57.3) 0.401
 Malignant biliary stricture 67 (33.3) 42 (39.6) 109 (35.5) 0.260
 Benign biliary stricture 11 (5.5) 4 (1.3) 15 (4.9) 0.437
 Biliary leakage 0 1 (0.9) 1 (0.3)  
 Pancreatic cyst 1 (0.5) 2 (1.9) 3 (1.0) 0.611
 Other indicationa 2 (1.0) 1 (0.9) 3 (1.0) 0.646
Procedures (%)
 Difficult cannulation 115 (57.2) 50 (47.2) 165 (53.7) 1.000
 P-duct manipulation 69 (34.3) 36 (34.0) 105 (34.2) 0.229
 Precut EST 70 (34.8) 34 (32.1) 104 (33.9) 0.729
 Pancreatic EST 44 (21.9) 17 (16.0) 61 (19.9) 1.000
 EPBD 21 (10.4%) 14 (13.2) 35 (11.4) 0.893
 ERPD 43 (21.4%) 15 (14.2) 58 (18.9) 1.000
  1. AP acute pancreatitis, SOD sphincter of Oddi dysfunction, ERCP endoscopic retrograde cholangiopancreatography, P-duct pancreatic duct, EST endoscopic sphincterotomy, EPBD endoscopic papillary balloon dilatation, ERPD endoscopic retrograde pancreatic drainage
  2. aIntraductal papillary neoplasm of bile duct, Mirrizi’s syndrome